The 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Podcast Central at ICAAC 2006
We asked three of the top U.S. HIV clinicians to give us their take on some of the most critical issues in HIV, including:
When should HIV therapy be initiated?
How do you choose an initial regimen?
What are the risks and benefits of structured treatment interruptions?
Why are people so excited about MK-0518, Merck's new integrase inhibitor?
Listen to each podcast to hear what these experts had to say. (Transcripts for each podcast are also available.)
Calvin J. Cohen, M.D., M.S., Community Research Initiative of New England and Harvard Medical School, Boston, Mass. Listen (8.7MB MP3, 25 min.) Read interview
Eric Daar, M.D., Harbor-UCLA Medical Center in Los Angeles, Calif. Listen (8.4MB MP3, 24 min.) Read interview
Benjamin Young, M.D., Ph.D., Denver ID Consultants, Rose Medical Center, Denver, Colo. Listen (7.6MB MP3, 22 min.) Read interview
Additional Podcasts
Robin Isaacs, M.D., Merck & Co., Inc.
We also had the opportunity to talk to Robin Isaacs, M.D., executive director of infectious disease and HIV vaccine research at Merck. He spoke about the MK-0518 data presented at ICAAC 2006. This new integrase inhibitor has shown impressive results both in treatment-experienced and treatment-naive HIV-infected patients. Listen (4.9MB MP3, 14 min.) Read interview
Gregory Smiley, American Academy of HIV Medicine, Washington, DC
Gregory Smiley is Director of Public Policy and Government Relations at the American Academy of HIV Medicine, an organization of 2,000 HIV specialists providing care to more than 340,000 people with HIV. Smiley discusses why the Ryan White CARE Act is an "anchor of [HIV] care" for HIV-infected people in the United States, and offers his view on why the U.S. Congress has taken so long to reauthorize it. Listen (8.3MB MP3, 24 min.) Read interview